South Korea's Celltrion Plans to Invest $1 Billion to Acquire, Expand U.S. Facility
By Kwanwoo Jun
South Korean biopharmaceutical company Celltrion plans to invest around $1 billion to acquire and expand a U.S. biologics facility in a bid to reduce U.S. tariff risks.
Celltrion said Tuesday that it plans to acquire the U.S. facility from Eli Lilly for 460 billion won, equivalent to $330.7 million. Including initial operating costs, it would spend 700 billion won in total.
Celltrion said it plans to invest an additional 700 billion won or more to expand the facility in Branchburg, N.J.
Under the agreement, Celltrion will complete the purchase from Eli Lilly by the end of the year.
Celltrion said the planned investment largely aims to remove U.S. tariff risks under the Trump administration.
"Celltrion is expected to remain fully protected from all potential future tariff risks," the company said in a statement.
Celltrion Group Chairman Seo Jung-jin said recently that in response to the tougher U.S. tariff policy, the company would acquire a manufacturing facility and expand contract manufacturing organization work in the U.S.
Write to Kwanwoo Jun at kwanwoo.jun@wsj.com
(END) Dow Jones Newswires
September 22, 2025 23:10 ET (03:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States